Coloma Jason V sold $907K of MAZE (indirect holdings)
Coloma Jason V (Chief Executive Officer) sold 34,501 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.29 ($26.29–$26.31, $0.91M total) across 2 trades on 2026-09-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale may lead to short‑term price pressure, though the amount is modest.
Market read
Primary insider transaction with modest size; limited trading relevance beyond MAZE.
What to watch
The 10b5‑1 plan pre‑arranges sales, reducing the signaling strength of the transaction.
Background
Form 4 filings disclose insider transactions; a CEO sale is noteworthy but often routine.
Ticker impact
CEO Jason V. Coloma sold 34,501 shares for $907K via a 10b5‑1 plan, reducing his stake to 223,355 shares.
Potential modest downside of 1‑2% over the next few days.
A $0.9M sale by the CEO signals possible concerns, but the amount is modest relative to market cap.
Market effects
Minimal impact on the biotech sector; insider sales are common and not sector‑wide.
No significant regional effect; the filing is U.S.‑focused.
Limited global relevance; only investors in MAZE are directly affected.
Counterpoint
The sale could be a routine liquidity event unrelated to company fundamentals.
Key entities
- OfficerJason V. Coloma
Chief Executive Officer of Maze Therapeutics, Inc.